However, the significant improvements in ORR and PFS suggest potential benefits and warrant further exploration in the development of anti-VEGF combination therapy, such as FTD/TPI plus ramucirumab in later-line treatment of gastric cancer [35]. Here, VEGFA is linked to gastric cancer.